{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-024939","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.958489+00:00","generated_at":"2026-06-19T00:47:14.860512+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Voyager closes Neurocrine collaboration, receives $175M; Neurocrine CSO joins board","bullets":["Collaboration Agreement effective; Neurocrine pays $136M upfront.","Neurocrine buys 4,395,588 shares at $8.88/share for ~$39M.","Jude Onyia, Ph.D., Neurocrine's CSO, appointed to board effective closing.","Onyia designated Class III director until 2024 annual meeting; Neurocrine retains nomination right while holding ≥10%.","Onyia receives standard non-employee director compensation: $40K cash retainer, initial option for 44,000 shares, annual option for 22,000 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-024939","json":"https://secwatch.observer/filing/0001104659-23-024939.json","markdown":"https://secwatch.observer/filing/0001104659-23-024939.md","text":"https://secwatch.observer/filing/0001104659-23-024939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/0001104659-23-024939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/tm237527d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T00:47:14.860512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cd568e406","claim":"Jude Onyia, Ph.D. was appointed as director at Voyager Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), approved the appointment of Jude Onyia, Ph.D., to serve as a director of the Company, contingent upon and effective as of the closing","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/0001104659-23-024939-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}